Summary of Product Characteristics Updated 20-Nov-2017 | Creo Pharma Limited
Lacidipine 4 mg film-coated tablets
Lacidipine 4 mg film-coated tablets
Each film-coated tablet contains lacidipine 4 mg.
Excipient with known effect: lactose anhydrous 274 mg.
For the full list of excipients, see section 6.1.
Lacidipine 4 mg film-coated tablets
White, oval [13 mm × 7.4 mm], biconvex, film-coated tablets with score line on one side.
The tablet can be divided into equal doses.
Lacidipine is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents, including ß-adrenoceptor antagonists, diuretics, and ACE-inhibitors.
The treatment of hypertension should be adapted to the severity of the condition, and according to the individual response.
The recommended initial dose is 2 mg once daily. The dose may be increased to 4 mg (and then, if necessary, to 6 mg) after adequate time has been allowed for the full pharmacological effect to occur. In practice, this should not be less than 3 to 4 weeks. Daily doses above 6 mg have not been shown to be significantly more effective. Lacidipine tablets should be taken at the same time each day, preferably in the morning. Treatment with Lacidipine may be continued indefinitely.
Patients with hepatic impairment
Lacidipine is metabolised primarily by the liver and therefore in patients with hepatic impairment, the bioavailability of Lacidipine may be increased and the hypotensive effect enhanced. These patients should be carefully monitored, and in severe cases, a dose reduction may be necessary.
Patients with kidney disease
As Lacidipine is not cleared by the kidneys, the dose does not require modification in patients with kidney disease.
The safety and efficacy of Lacidipine in children and adolescents aged below 18 have not been estabilished. No data are available.
Method of administration
For oral administration
Lacidipine tablets are contraindicated in patients with known hypersensitivity to any ingredient of the preparation.
Lacidipine should only be used with great care in patients with a previous allergic reaction to another dihydropyridine because there is a theoretical risk of cross-reactivity.
As with other calcium antagonists, Lacidipine should be discontinued in patients who develop cardiogenic shock and unstable angina. In addition, dihydropyridines have been shown to reduce coronary arterial blood-flow in patients with aortic stenosis and in such patients Lacidipine is contraindicated.
Lacidipine should not be used during or within one month of a myocardial infarction.
In case of rare hereditary conditions that may be incompatible with an excipient of the product (please refer to section 4.4 Special Warnings and Precautions for Use) the use of the product is contraindicated.
In specialised studies lacidipine has been shown not to affect the spontaneous function of the SA node or to cause prolonged conduction within the AV node. However, the theoretical potential for a calcium antagonist to affect the activity of the SA and AV nodes should be noted, and therefore Lacidipine should be used with caution in patients with pre-existing abnormalities in the activity of the SA and AV nodes.
As has been reported with other dihydropyridine calcium channel antagonists, lacidipine should be used with caution in patients with congenital or documented acquired QT prolongation. Lacidipine should also be used with caution in patients treated concomitantly with medications known to prolong the QT interval such as class I and III antiarrhythmics, tricyclic antidepressants, some antipsychotics, antibiotics (e.g. erythromycin) and some antihistamines (e.g. terfenadine).
As with other calcium antagonists, lacidipine should be used with caution in patients with poor cardiac reserve.
There is no evidence that lacidipine is useful for secondary prevention of myocardial infarction.
The efficacy and safety of Lacidipine in the treatment of malignant hypertension has not been established.
Lacidipine should be used with caution in patients with impaired liver function because antihypertensive effect may be increased.
There is no evidence that lacidipine impairs glucose tolerance or alters diabetic control.
This product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Other anti-hypertensive agents
Co-administration of Lacidipine with other agents recognized to have a hypotensive effect, including anti-hypertensive agents (e.g. diuretics, beta-blockers or ACE-inhibitors) may have an additive hypotensive effect. However, no specific interaction problems have been identified in studies with common antihypertensive agents (e.g. beta-blockers and diuretics) or with digoxin, tolbutamide or warfarin.
The plasma level of lacidipine may be increased by simultaneous administration of cimetidine.
Lacidipine is highly protein-bound (more than 95%) to albumin and alpha-1-glycoprotein.
As with other dihydropyridines, Lacidipine should not be taken with grapefruit juice as bioavailability may be altered.
In clinical studies in patients with a renal transplant treated with cyclosporin, lacidipine reversed the decrease in renal plasma flow and glomerular filtration rate induced by cyclosporin.
Lacidipine is known to be metabolized by cytochrome CYP3A4 and, therefore, significant inhibitors and inducers of CYP3A4 (e.g. rifampicin, itraconazole) administered concurrently may interact with the metabolism and elimination of lacidipine.
Concomitant use of lacidipine and corticoids or tetracosactide might decrease antihypertensive effect of lacidipine.
There are no data on the safety of lacidipine in human pregnancy.
Although some calcium channel blockers have been found to be teratogenic in animals, studies with lacidipine in animals have not shown malformations. Using doses far above the therapeutic range, in animals lacidipine shows evidence of maternal toxicity resulting in increased pre- and post-implantation losses and possibly delayed ossification. Evidence from experimental animals has indicated that administration of lacidipine results in prolongation of gestational period and prolonged and difficult labour as a consequence of relaxation of uterine muscle. There are no data on the safety of lacidipine in human pregnancy.
The possibility that lacidipine can cause relaxation of the uterine muscle at term should be considered (see section 5.3)
Lacidipine should only be used in pregnancy when the potential benefits for the mother outweigh the possibility of adverse effects in the foetus or neonate.
Milk transfer studies in animals have shown that lacidipine (or its metabolites) are likely to be excreted into breast milk.
Lacidipine should only be used during breastfeeding when the potential benefits for the mother outweigh the possibility of adverse effects in the foetus or neonate.
Lacidipine tablets may cause dizziness. Patients should be warned not to drive or operate machinery if they experience dizziness or related symptoms.
Lacidipine tablets are generally well tolerated.
Some individuals may experience minor side effects which are related to its known pharmacological action of peripheral vasodilation. Such effects, indicated by a hash #, are usually transient and usually disappear with continued administration of lacidipine at the same dosage.
Data from large clinical studies (internal and published) were used to determine the frequency adverse effects.
Adverse effects have been ranked under headings of frequency using the following convention:
≥ 1/100, <1/10
≥ 1/1000, <1/100
≥ 1/10000, <1/1000
cannot be estimated from the available data
In each group adverse effects are presented with decreasing severity.
Nervous system disorders
As with other dihydropyridines aggravation of underlying angina pectoris has been reported in a small number of individuals, especially at the start of treatment. This is more likely to happen in patients with symptomatic ischaemic heart disease. Lacidipine should be discontinued under medical supervision in patients who develop unstable angina.
#flushing (especially of face)
abdominal discomfort, nausea
Skin and subcutaneous tissue disorders
rash, erythema, pruritus
Musculoskeletal and connective tissue disorders
Renal and urinary disorders
General disorders and administration site conditions
blood alkaline phosphatase increased
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme: www.mhra.gov.uk/yellowcard.
There have been no recorded cases of Lacidipine tablets overdosage. The expected symptoms could comprise prolonged peripheral vasodilation associated with hypotension and tachycardia. Bradycardia or prolonged AV conduction could occur.
There is no specific antidote. Standard general measures for monitoring cardiac function and appropriate supportive and therapeutic measures should be used.
Pharmacotherapeutic group: Calcium channel blockers, dihydropyridine derivatives
ATC code: C08CA09
Mechanism of action
Lacidipine is a specific and potent calcium antagonist with a predominant selectivity for calcium channels in the vascular smooth muscle.
Its main action is to dilate peripheral arterioles, reducing peripheral vascular resistance and lowering blood pressure.
In a study of ten patients with a renal transplant, lacidipine has been shown to prevent an acute decrease in renal plasma flow and glomerular filtration rate about six hours after administering oral cyclosporin. During the trough phase of cyclosporin treatment, there was no difference in renal plasma flow and glomerular filtration rate between patients with or without lacidipine.
Following the oral administration of 4 mg lacidipine to volunteer subjects, a minimal prolongation of QTc interval has been observed (mean QTcF increase between 3.44 and 9.60 ms in young and elderly volunteers). This was not associated with any adverse clinical effects or cardiac arrhythmias on monitoring.
Lacidipine is a highly lipophilic compound; it is rapidly absorbed from the gastrointestinal tract following oral dosing.
Absolute bioavailability averages about 10% due to extensive first-pass metabolism in the liver.
Peak plasma concentrations are reached between 30 and 150 minutes.
The principal four metabolites possess little, if any, pharmacodynamic activity.
The drug is eliminated primarily by hepatic metabolism (involving cytochrome P450 CYP3A4). There is no evidence that Lacidipine causes either induction or inhibition of hepatic enzymes.
Approximately 70% of the administered dose is eliminated as metabolites in the faeces and the remainder as metabolites in the urine.
The average terminal half-life of lacidipine ranges from between 13 and 19 hours at steady state.
In acute toxicity studies, Lacidipine has shown a wide safety margin.
In repeated dose toxicological studies, findings in animals, related to the safety profile of Lacidipine in man, were reversible and reflected the pharmacodynamic effect of Lacydipine.
No data of clinical relevance have been gained from in vivo and in vitro studies on reproduction toxicity, genetic toxicity or oncogenicity.
Titanium dioxide (E171).
Store in the original package in order to protect from light.
OPA/Aluminium/PVC/Aluminium blisters placed into a carton.
Lacidipine 4 mg film-coated tablets – 7, 14, 28, 56 film-coated tablets
Not all pack sizes may be marketed.
The tablets should not be removed from their foil pack until required for administration.
Lacidipine, 4 mg, film-coated tablets
If, in accordance with the recommended dosage, patients take a half tablet of 4 mg, then the unused half should be kept out of direct light and taken within 48 hours.
No special requirements for disposal.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Creo Pharma Limited
Felsted Business Centre,
Felsted Business Centre, Felsted, Essex, CM6 3LY
+44 (0)1371 822 022
+44 (0)1371 823 933
+44 (0)1371 822 022
+44 (0) 8448 793188
+44 (0)1371 822 044
+44 (0)1371 822 044